Healthcare
Live Price
Offline$0.117
+0.00% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Creso Pharma Limited (COPHF) is a Healthcare stock with a market cap of $131.72M. The stock last traded around $0.12. Baseline metrics include revenue growth of +117.8%, EPS growth of +100.0%, a dividend yield of 0.0%. What stands out right now is revenue +117.8%, EPS +100.0%, free cash flow +72.9% with operating margin -225.2% and ROIC -67.6%. Valuation is more restrained than many high-expectation growth names at price/sales 2.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines COPHF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
COPHF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
COPHF Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for COPHF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.6M
+48.2% YoY
FY Net Income
-$17.1M
+54.6% YoY
Free Cash Flow
-$13.5M
-34.4% YoY
Revenue Growth
+117.8%
EPS Growth
+100.0%
Gross Margin
3.3%
Net Margin
-377.3%
Income statement
AUD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 19M | 9M | 6M | 2M | 4M |
| Gross Profit | 2M | 287K | -401K | -4M | 2M |
| Operating Income | -17M | -20M | -28M | -17M | -10M |
| EBITDA | -25M | -18M | -28M | -16M | -10M |
| Net Income | -52M | -33M | -32M | -38M | -17M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
AUD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 692K | 1M | 7M | 6M | 3M |
| Total Assets | 19M | 38M | 29M | 19M | 23M |
| Total Liabilities | 23M | 16M | 2M | 5M | 5M |
| Shareholder Equity | -4M | 22M | 28M | 14M | 18M |
| Total Debt | 10M | 7M | 0 | 3M | 3M |
| Net Debt | 9M | 5M | -7M | -3M | 427K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
10M
-5.7% YoY
Capital Expenditures
3M
-678.8% YoY
Free Cash Flow
14M
-34.4% YoY
Key ratios
Gross Margin
3.3%
Operating Margin
-225.2%
Net Margin
-377.3%
ROE
-131.0%
Debt / Equity
0.30x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.